Recent studies have identified potentially clinical roles of MAP3K3 as an oncogene that promotes cancer progression in several different malignancies including non‐small‐cell lung cancer, ovarian carcinoma, lung cancer and renal clear cell carcinoma 14, 21, 22, 23. Here, MAP3K3 is linked to lung carcinoma.